Table II.
Local treatment outcome of liver metastasis from breast cancer (review and present study).
| First author | Patient population, n | Number (S/M) | Distribution (unilateral/bilateral) | Size, cm (cut-off value, patient no.) | Treatment | 1/3/5-year OS rate, % (median, years) | 1/3/5-year PFS rate, % (median, years) | (Refs.) |
|---|---|---|---|---|---|---|---|---|
| Hoffmann | 29 | SU | −/75/59 | (21) | ||||
| Adam | 85 | 32/53 | 52/33 | <5/≥5, 71/14 | SU | −/−/41 (3.8) | −/−/17 | (20) |
| Vlastos | 31 | 20/11 | <2/≥2, 11/20 | SU | −/−/61 (5.3) | −/−/31 | (22) | |
| Abbott | 86 | 53/33 | <5/≥5, 73/13 | SU | (4.8) | (1.2) | (23) | |
| Pocard | 52 | 36/16 | 28/24 | <3/≥3, 9/12 | SU | 86/49/− | (24) | |
| Li | 29 | TACE | 63/13/− | (27) | ||||
| Vogl | 159 | TACE | 64/36/− | (26) | ||||
| Duan | 44 | TACE+C | 76/48/− (2.6) | (25) | ||||
| Present study | 8 | 5/3 | 8/0 | <5/≥5, 5/2 | PBT | 88/73/58 | 50/25/0 (0.8) |
S, solitary; M, multiple; OS, overall survival; PFS, progressionfree survival; SU, surgery; C, chemotherapy; TACE, transcatheter arterial chemoembolization; PBT, proton beam therapy.